Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: Results from NHANES III

Journal of Gastroenterology

Volumn 48, Issue 10, 2013, Pages 1151-1159

  Liu, Su Hsun ^a   Lazo, Mariana ^a   Koteish, Ayman ^b   Kao, W H Linda ^a   Shih, Ming Hsiung ^c   Bonekamp, Susanne ^b   Hernaez, Ruben ^a,b,d   Clark, Jeanne M ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Adiposity; Nonalcoholic fatty liver disease; Obesity; Oral contraceptive pill; Sex hormone

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; BODY MASS; DIABETES MELLITUS; ECHOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MENSTRUATION; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; STUDY; WAIST CIRCUMFERENCE; YOUNG ADULT;

ADULT; CONTRACEPTIVES, ORAL; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; LIVER; MENSTRUATION; MIDDLE AGED; PREVALENCE; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84892830656     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0715-8     Document Type: Article

References (43)

1. Angulo P. Nonalcoholic fatty liver disease. NEJM. 2002; 346: 1221-31.
2. Lazo M, Clark JM The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28:339-50.
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P., Horton JD, Cohen JC, et al Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40:1387-95.
4. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006; 40(SUPPL. 1):S5-10.
5. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol. 2009; 50:797-804.
6. Gutierrez-Grobe Y., Ponciano-Rodriguez G, Ramos M.H., Uribe M., Mendez-Sanchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010; 9: 402-9.
7. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res. 2007; 37:239-47.
8. Elbers JM, de Roo GW, Popp-Snijders C, Nicolaas-Merkus A, Westerveen E., Joenje BW, et al. Effects of administration of 17beta-oestradiol on serum leptin levels in healthy postmeno-pausal women. Clin Endocrinol (Oxf). 1999; 51:449-54.
9. Haarbo J, Marslew U, Gotfredsen A., Christiansen C. Postmeno-pausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism. 1991; 40:1323-6.
10. Witteman J, Grobbee D, Kok F., Hofman A, Valkenburg H. Increased risk of atherosclerosis in women after the menopause. Br Med J. 1989; 298:642-4.
11. Bjoerkelund C, Lissner L, Andersson S., Lapidus L, Bengtsson C. Reproductive history in relation to relative weight and fat distribution. Int J Obes. 1996; 20:213-9.
12. Saruç M, Yüceyar H, Ayhan S, Türkel N, Tuzcuoglu I, Can M. The association of dehydroepiandrosterone, obesity, waist-hip ratio and insulin resistance with fatty liver in postmenopausal women-a hyperinsulinemic euglycemic insulin clamp study. Hepatogastroenterology. 2003; 50:771-4.
13. Clark JM, Brancati FL, Diehl AM Nonalcoholic fatty liver disease. Gastroenterology. 2002; 122:1649-57.
14. McKenzie J, Fisher BM, Jaap A.J., Stanley A., Paterson K, Sattar N. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2006; 65:40-4.
15. Park SH, Jeon WK, Kim S.H., Kim HJ, Park DI, Cho YK, et al Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006; 21:138-43.
16. National Center for Health Statistics. NHANES III data files, documentation and codebooks; 2011. http://www.cdc.gov/nchs/nhanes/nh3data.htm. Accessed 16 Nov 2012.
17. Harlow SD, Gass M, Hall J.E., Lobo R., Maki P, Rebar RW, et al Executive summary of the Stages of Reproductive Aging Workshop? 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012; 97:1159-68.
18. Hamaguchi M, Kojima T, Itoh Y., et al The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007; 102:2708-15.
19. Centers for Disease Control and Prevention. Alcohol and Public Health. Frequently asked questions: what is a standard drink in the United States? 2012. http://www.cdc.gov/alcohol/faqs.htm#standDrink. Accessed 16 Nov 2012.
20. National Center for Health Statistics. Third National Health and Nutrition Survey: hepatic steatosis assessment procedure manual. 2010. http://www.cdc.gov/nchs/data/nhanes/nhanes3/Hepatic-Steatosis-Ultrasound- Procedures-Manual.pdf. Accessed on 16 Nov 2012.
21. Bonora E, Targher G, Alberiche M., Bonadonna RC, Saggiani F, Zenere MB, et al Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23:57-63.
22. Chumlea WC, Guo SS, Kuczmarski R.J., Flegal KM, Johnson CL, Heymsfield SB, et al Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord. 2002; 26:1596-609.
23. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992; 11:167-78.
24. VanderWeele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol. 2010; 172: 1339-48.
25. StataCorp. Stata Statistical Software: release 11. College Station: StataCorp LP; 2009.
26. Gallo MF, Lopez LM, Grimes D.A., Schulz KF, Helmerhorst FM Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2011;(9). doi:10.1002/14651858.CD003987.pub4.
27. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007; 28:521-74.
28. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010; 10:338-49.
29. Pfeilschifter J, Köditz R, Pfohl M., Schatz H. Changes in proin-flammatory cytokine activity after menopause. Endocr Rev. 2002; 23:90-119.
30. Rogers AER. The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. Bone. 2001; 29:30-4.
31. Lacort M, Leal AM, Liza M, Martín C, Martínez R, Ruiz-Larrea MB. Protective effect of estrogens and catecholestro-gens against peroxidative membrane damage in vitro. Lipids. 1995; 30:141-6.
32. Omoya T, Shimizu I, Zhou Y., Okamura Y, Inoue H, Lu G., et al. Effects of idoxifene and estradiol on NF-kappaB activation in cultured rat hepatocytes undergoing oxidative stress. Liver. 2001; 21:183-91.
33. Caprio M, Zennaro MC, Feve B, Mammi C., Fabbri A, Rosano G. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with the mineralocorticoid receptor. Climacteric. 2008; 11:258-64.
34. Lacasa D, Le Liepvre X, Ferre P, Dugail I. Progesterone stimulates adipocyte determination and differentiation 1/sterol regulatory element-binding protein 1c gene expression. Potential mechanism for the lipogenic effect of progesterone in adipose tissue. J Biol Chem. 2001; 276:11512-6.
35. Kjeld JM, Puah CM, Joplin GF Changed levels of endogenous sex steroids in women on oral contraceptives. Br Med J. 1976; 2:1354-6.
36. Gaspard UJ, Romus MA, Gillain D, Duvivier J., Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levo-norgestrel or desogestrel. Contraception. 1983; 27:577-90.
37. Caldwell SH, Harris DM, Patrie J.T., Hespenheide EE Is NASH underdiagnosed among African Americans? Am J Gastroenterol. 2002; 97:1496-500.
38. Solga SF, Clark JM, Alkhuraishi A.R., Torbenson M., Tabesh A, Schweitzer M, et al Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis. 2005; 1:6-11.
39. Conway JM, Yanovski SZ, Avila N.A., Hubbard VS Visceral adipose tissue differences in black and white women. Am J Clin Nutr. 1995; 61:765-71.
40. Lovejoy JC, de la Bretonne JA, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism. 1996; 45:1119-24.
41. Randolph JF Jr., Sowers M, Gold E.B., Mohr BA, Luborsky J, Santoro N, et al Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab. 2003; 88:1516-22.
42. Randolph JF J.r., Sowers M, Bondarenko I.V., Harlow SD, Lubor-sky JL, Little RJ Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab. 2004; 89:1555-61.
43. Ukkola O, Gagnon J, Rankinen T., Thompson PA, Hong Y, Leon AS, et al Age, body mass index, race and other determinants of steroid hormone variability: the HERITAGE Family Study. Eur J Endocrinol. 2001; 145:1-9.